Clinical Application of Immune Checkpoint Inhibitors in Bladder Cancer

Gain expert perspective on optimal use of promising new checkpoint inhibitors for patients with bladder cancer through 4 downloadable PowerPoint slidesets and a Webcast.
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS
David I. Quinn, MBBS, PhD, FRACP, FACP
Jonathan E. Rosenberg, MD

Downloadable Slidesets

In this downloadable slideset, Daniel P. Petrylak, MD, reviews the immune-related toxicities associated with checkpoint inhibitor therapy presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 6, 2016

In this downloadable slideset, Jonathan E. Rosenberg, MD, reviewed key data in the clinical development of immune checkpoint inhibitors in advanced bladder cancer presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 6, 2016

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, reviews the key issues and controversies with moving checkpoint inhibitor therapy into the clinic for advanced bladder cancer presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 6, 2016

In this downloadable slideset, David I Quinn, MBBS, PhD, FRACP, FACP reviews the rationale and mechanism of action of immunotherapy in bladder cancer presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 6, 2016

On-Demand Webcasts

Watch the video from our live symposium at ASCO 2016 in Chicago. In this segment, Daniel P. Petrylak, reviews the characteristics and management of adverse events that are unique to immune checkpoint inhibitor therapy.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 16, 2016

Watch the video from our live symposium at ASCO 2016 in Chicago. In this first segment, Daniel P. Petrylak, MD introduces the panel and provides an overview for the program.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 16, 2016

Watch the video from our live symposium at ASCO 2016 in Chicago. In this final segment, Elizabeth R. Plimack, MD, MS, describes the salient and controversial issues around moving checkpoint inhibitors into the clinic for patients with urothelial cancer.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 16, 2016

Watch the video from our live symposium at ASCO 2016 in Chicago. In this segment, David I. Quinn, MBBS, PhD, FRACP, FACP, reviews the mechanism of action of immune checkpoint inhibitors and other immunotherapies in urothelial cancer.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 16, 2016

Watch the video from our live symposium at ASCO 2016 in Chicago. In this segment, Jonathan E. Rosenberg, MD, reviews the clinical development and future directions of immune checkpoint inhibitors in the treatment of urothelial cancer.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS David I. Quinn, MBBS, PhD, FRACP, FACP Jonathan E. Rosenberg, MD Released: June 16, 2016
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by educational grants from
Genentech
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?